PD-L1 positive, EGFR-negative, ALK-negative metastatic non-small cell lung cancer

This indication describes advanced epithelial malignancy arising in the respiratory tract that has disseminated beyond the primary thoracic site to distant organs or tissues Simultaneously, the disease is clinically characterized by the documented absence of actionable oncogenic driver alterations in the epidermal growth factor receptor (*EGFR*) gene and anaplastic lymphoma kinase (*ALK*) gene

This indication describes advanced epithelial malignancy arising in the respiratory tract that has disseminated beyond the primary thoracic site to distant organs or tissues

Pathophysiologically, the tumor cells demonstrate surface expression of programmed death-ligand 1 (PD-L1), a transmembrane checkpoint protein that facilitates immune evasion by inhibiting cytotoxic T-cell activity This distinct molecular profile defines a patient population whose advanced malignancy lacks standard tyrosine kinase inhibitor targets but exhibits biological susceptibility to immune checkpoint blockade

Pathophysiologically, the tumor cells demonstrate surface expression of programmed death-ligand 1 (PD-L1), a transmembrane checkpoint protein that facilitates immune evasion by inhibiting cytotoxic T-cell activity

Simultaneously, the disease is clinically characterized by the documented absence of actionable oncogenic driver alterations in the epidermal growth factor receptor (*EGFR*) gene and anaplastic lymphoma kinase (*ALK*) gene This distinct molecular profile defines a patient population whose advanced malignancy lacks standard tyrosine kinase inhibitor targets but exhibits biological susceptibility to immune checkpoint blockade